ReCode Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 15
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $80M
Latest Deal Amount
  • Investors
  • 8

ReCode Therapeutics General Information

Description

Developer of biopharmaceutical technology intended to address the correction of the nonsense mutations. The company develops a suppressor tRNA delivery to treat nonsense mutations, helping lung cells to override premature stop signals and make full-length, functional CFTR protein.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Primary Office
  • 1455 Adams Drive
  • Menlo Park, CA 94025
  • United States
+1 (408) 000-0000

ReCode Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReCode Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 26-Mar-2020 $80M 0000 Completed Clinical Trials - General
1. Early Stage VC 08-Feb-2019 000 000 Completed Clinical Trials - General
To view ReCode Therapeutics’s complete valuation and funding history, request access »

ReCode Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
David Lockhart Chief Executive Officer, Board Member and President
Arthur Johnson President
Daniel Siegwart Ph.D Co-Founder
Philip Thomas Ph.D Co-Founder
Michael Torres Ph.D Co-Founder, Vice President of Research & Development & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

ReCode Therapeutics Board Members (7)

Name Representing Role Since
David Lockhart ReCode Therapeutics Chief Executive Officer, Board Member and President 000 0000
Edward Hurwitz ReCode Therapeutics Board Member 000 0000
Helen Kim ReCode Therapeutics Board Member 000 0000
Michael Torres Ph.D ReCode Therapeutics Co-Founder, Vice President of Research & Development & Board Member 000 0000
Peter Thompson ReCode Therapeutics Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

ReCode Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReCode Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Colt Ventures Venture Capital Minority 000 0000 000000 0
Evolution VC Partners Venture Capital Minority 000 0000 000000 0
Hunt Technology Ventures Other Minority 000 0000 000000 0
MPM Capital Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

ReCode Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 06-Mar-2020 000000000000000000 0000 Biotechnology
To view ReCode Therapeutics’s complete acquisitions history, request access »